Heidy King-Jones - 01 Sep 2026 Form 4 Insider Report for Spyre Therapeutics, Inc. (SYRE)

Reporting relationship: Officer
Issuer ticker: SYRE
Reported as of: 01 Sep 2026
Net transaction value: -$2,480,529
SEC form: 4
Accepted by SEC: 03 Sep 2026, 21:34:14 UTC
Prior SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Heidy King-Jones

Key filing fact

Heidy King-Jones filed Form 4 for Spyre Therapeutics, Inc. (SYRE) on 03 Sep 2026.

Key facts

This page summarizes Heidy King-Jones's Form 4 filing for Spyre Therapeutics, Inc. (SYRE).
9 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 21:34.

Change

Previous filing in this sequence was filed on 13 Jan 2026.
Current net transaction value: -$2,480,529.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001794898 Primary reporting owner

King-Jones Heidy

Relationship: Officer
Address: 221 CRESCENT STREET, BUILDING 23,, SUITE 105, WALTHAM
Signature: /s/ Heidy King-Jones
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SYRE transaction

Common Stock

Options Exercise

Transaction value
Shares: +27,999
Change %: +984%
Price: $14.50^*
Shares after: 30,844
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2

SYRE transaction

Common Stock

Sale

Transaction value: $418,608
Shares: -4,845
Change %: -16%
Price: $86.40
Shares after: 25,999
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3

SYRE transaction

Common Stock

Sale

Transaction value: $1,442,986
Shares: -16,548
Change %: -64%
Price: $87.20
Shares after: 9,451
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F4

SYRE transaction

Common Stock

Sale

Transaction value: $547,183
Shares: -6,206
Change %: -66%
Price: $88.17
Shares after: 3,245
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F5

SYRE transaction

Common Stock

Sale

Transaction value: $35,752
Shares: -400
Change %: -12%
Price: $89.38
Shares after: 2,845
Date: 01 Sep 2026
Ownership: Direct
Footnotes: F1, F2

SYRE transaction

Common Stock

Options Exercise

Transaction value
Shares: +400
Change %: +14%
Price: $14.50^*
Shares after: 3,245
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F1, F2

SYRE transaction

Common Stock

Sale

Transaction value: $36,000
Shares: -400
Change %: -12%
Price: $90.00
Shares after: 2,845
Date: 02 Sep 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SYRE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -27,999
Change %: -5.2%
Price: $0.000000^*
Shares after: 511,811
Date: 01 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,999
Exercise price: $14.50
Footnotes: F1, F6

SYRE transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -400
Change %: -0.08%
Price: $0.000000^*
Shares after: 511,411
Date: 02 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400
Exercise price: $14.50
Footnotes: F1, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on April 16, 2026.

Footnote F2

Includes 489 shares of common stock acquired by the Reporting Person on August 15, 2024, 495 shares of common stock acquired by the Reporting Person on February 15, 2025, 850 shares of common stock acquired by the Reporting Person on August 15, 2025, 325 shares of common stock acquired by the Reporting Person on December 31, 2025, and 686 shares of common stock acquired by the Reporting Person on June 30, 2026 pursuant to the Issuer's employee stock purchase plan.

Footnote F3

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.71 to $86.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F4

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.71 to $87.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F5

The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $87.73 to $88.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.

Footnote F6

This option represents the right to purchase 539,810 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.